Defunct Company
Total Trials
27
As Lead Sponsor
14
As Collaborator
13
Total Enrollment
3,217
NCT00096707
Dose Escalation Trial of 2-Deoxy-D-Glucose (2DG) in Subjects With Advanced Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: Feb 29, 2004
Completion: Jul 31, 2008
NCT00099294
Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer
Phase: Phase 3
Start: Sep 30, 2004
Completion: Jan 31, 2007
NCT00102752
Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
Phase: Phase 1/2
Start: Dec 31, 2004
Completion: Jul 31, 2007
NCT00237536
Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Phase: Phase 2
Start: Jun 30, 2005
Completion: Aug 31, 2006
NCT00435448
Completion: Dec 31, 2006
NCT00435578
Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma
Start: Feb 28, 2007
Completion: Nov 30, 2007
NCT00441467
Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma
Role: Collaborator
Start: Mar 31, 2007
Completion: Oct 31, 2008
NCT00495144
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Start: Jun 30, 2007
Completion: Jun 30, 2012
NCT00743379
Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
Start: Aug 31, 2008
Completion: Mar 31, 2014
NCT01149915
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
Start: Jun 30, 2010
Completion: Aug 31, 2013
NCT01381822
Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors
Start: Jun 30, 2011
Completion: Jun 30, 2014
NCT01440088
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Start: Sep 30, 2011
Completion: May 31, 2016
NCT01485042
Dose Escalation Study of Pazopanib Plus TH-302
Start: Dec 31, 2011
NCT01522872
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Start: Feb 29, 2012
Completion: Sep 30, 2017
NCT01497444
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Start: May 31, 2012
Completion: Nov 1, 2019
NCT01746979
Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Start: Dec 31, 2012
NCT01833546
A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
Start: Apr 18, 2013
Completion: Jan 25, 2016
NCT02020226
A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors
Start: Nov 30, 2013
Completion: Dec 31, 2016
NCT02047500
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
Start: Jan 31, 2014
NCT02076230
A Phase 1 TH-302 Mass Balance Trial
Start: Feb 28, 2014
Completion: Mar 31, 2016
NCT02255110
A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Start: Dec 10, 2014
Completion: Jan 12, 2016
NCT01721941
TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma
Start: Dec 31, 2014
NCT02433639
Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer
Start: Apr 30, 2015
Completion: Oct 31, 2017
NCT02402062
A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
Start: May 11, 2015
Completion: Jan 10, 2020
NCT02598687
Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer.
Start: Dec 31, 2015
Completion: Apr 30, 2016
NCT03098160
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
Start: May 10, 2017
Completion: Apr 30, 2019